Breast cancer and its treatments are an assault to a woman's body, placing her at risk for numerous sequelae. Cardiotoxicity associated with treatment using doxorubicin (DOX) and trastuzumab is of particular concern. Both are effective cytotoxic agents, 4, 5 but the potential for acute and chronic cardiotoxic effects limits dose and duration of use. Animal model studies have shown the cardioprotective effect of exercise in animals receiving DOX and are of promise. [6] [7] [8] [9] [10] [11] [12] [13] However, clinical literature investigating the cardioprotective benefits of exercise training on women undergoing therapy with the combination of DOX and trastuzumab is scant. To our knowledge, no published studies exist that address the cardioprotective benefits of exercise in women diagnosed with breast cancer and treated with the combination of DOX and trastuzumab. Further research to determine whether exercise therapy attenuates cardiotoxicity in women with breast cancer who are treated with these agents is warranted. Therefore, the purpose of this article is to review the cardiovascular effects of DOX and trastuzumab combination therapy for ErbB2-overexpressing breast cancer, so that clinicians will be better able to care for this emerging
Introduction
Invasive breast cancer remains a major health problem for women. More than 180 000 women are expected to develop invasive breast cancer in 2008, and more than 40 000 will die of the disease. 1 Most women diagnosed with breast cancer are treated using a multimodality approach. Typically, surgery is the primary treatment accompanied by adjuvant therapies such as irradiation, chemotherapy, and hormonal therapy. 2 Such therapies are selected on the basis of patient age, comorbidities, and physiological status as well as tumor size, lymph node involvement, histological grade, estrogen and progesterone receptor status, and human epidermal growth factor receptor 2 (ErbB2) status. For the approximately 25% of women whose tumors possess the ErbB2 alteration, 1 year of adjuvant trastuzumab is recommended either with or following chemotherapy. 3
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Trastuzumab Trastuzumab (Herceptin) was approved in 1998 by the Food and Drug Administration for the treatment of metastatic breast cancer that overexpresses the oncoreceptor ErbB2. 14 ErbB2 (also called c-neu or HER-2) is a tyrosine kinase derived from the ErbB family, a family of genes involved in the regulation of normal breast growth and development. 15 The tyrosine kinases comprise 4 structurally related transmembrane receptors, epidermal growth factor receptor-1 (EGFR)/ErbB1, ErbB2, ErbB3, and ErbB4. Activation of the ErbB receptors may occur by ligand binding 16 or overexpression of the receptor. 17 Ligand binding results in the activation of intracellular pathways involved in the regulation of cell proliferation 18 and apoptosis. 19 Overexpression of ErbB receptors is generally attributable to gene amplification 20 and occurs in approximately 20% to 30% of breast cancers. 21, 22 The overexpression of ErbB2 is associated with neoplastic transformation and the development of tumors 23 as well as with shorter time to relapse and lower overall survival. 20, 21 Trastuzumab is a humanized version of the monoclonal antibody 4D5 used in the treatment of patients with breast cancer overexpressing ErbB2 receptors. 24 Trastuzumab arrests cells in the G 1 -phase of the cell cycle, 25 where it binds to the extracellular domain of active ErbB2 receptors, causing inhibition of ErbB2-mediated malignant transformation. 23 This leads to the downregulation of ErbB2 expression in the plasma membrane and increases its turnover, resulting in trastuzumab-induced endocytosis of ErbB2. This is considered to be an important anticancer mechanism because reducing the level of ErbB2 at the plasma membrane will decrease signaling from ErbB2 and downregulate ErbB2-induced cell proliferation. 25 In clinical settings, trastuzumab is approved for the treatment of ErbB2-positive metastatic breast cancer at an initial dose of 4 mg/kg intravenously over 90 minutes followed by weekly doses of 2 mg/kg over 30 minutes. 26 It is often used as a single agent either before or following chemotherapy and in combination with chemotherapy agents in women with ErbB2-overexpressing metastatic breast cancer. 27 Research has demonstrated that the overexpression of ErbB2 affects the sensitivity of breast cancer cells to anticancer agents 15 and may, in fact, confer resistance to certain forms of chemotherapy, specifically cyclophosphamide-and taxane-based regimens. 28 Conversely, trastuzumab exerts an additive effect on the antitumor activity of DOX, making trastuzumab and DOX combination therapy the standard of treatment for women with ErbB2-overexpressing metastatic breast cancer. 29 DOX is a potent chemotherapy agent used in the treatment of a variety of cancers. Its primary antineoplastic mechanism involves intercalation into DNA. DOX enters cells in the G 1 -phase of the cell cycle via simple diffusion. Once inside the cell, DOX binds to a proteasome in the cytoplasm. The DOX-proteasome complex then translocates to the nucleus, where DOX dissociates from the proteasome and binds to DNA. On intercalation, the daunosamine sugar of DOX inserts into the minor groove of the DNA double helix, thereby inhibiting topoisomerase II and preventing DNA replication. In cancer cells, this is effective in preventing cancer cell growth and proliferation. 30 As a single agent, the typical dose of DOX is 75 mg/ m 2 , administered intravenously every 3 weeks. However, when used in combination with other agents, recommended doses of DOX are often reduced to a range of 50 to 60 mg/m 2 administered every 3 weeks. 31 Clinical studies have found that trastuzumab and DOX combination treatment is associated with higher response rates, longer progression-free survival, and longer overall survival compared with DOX treatment alone. 15, 27 
Trastuzumab and Doxorubicin Cardiotoxicity
One side effect of the treatment of metastatic breast cancer with trastuzumab and DOX is the development of a dose-dependent cardiotoxicity, characterized by an increase in left-ventricular dysfunction and symptomatic heart failure. The incidence of left-ventricular dysfunction is approximately 3% to 18%, with a corresponding rate of heart failure that is roughly 2.0% to 4.1%. 32 In fact, the rates of cardiotoxicity are so high that concurrent administration of DOX and trastuzumab is contraindicated, despite its clinical efficacy. Thus, all large adjuvant trials 33 have evaluated only the sequential strategy of trastuzumab and DOX administration. Even with sequential therapy, cardiac dysfunction remains an important clinical issue. Contributing factors to cardiac dysfunction include poor baseline cardiac function, reduced left-ventricular ejection fraction following chemotherapy, advanced age, and previous or concurrent treatment with DOX. 34 Finally, it is of note that the current follow-up in all adjuvant trials is relatively short, and the long-term cardiac effects of trastuzumab-based regimens remain unknown. Because it is possible for the onset of DOXinduced cardiotoxicity to be delayed for up to 20 years, 35 long-term follow-up care is warranted.
Trastuzumab as a single agent is generally considered to be well tolerated in patients because ErbB2 is expressed at low levels in normal tissue, and therefore, damage to normal cells is minimized. 22 On the other hand, the occurrence of a dose-related cardiomyopathy largely limits the prolonged clinical use of DOX. An acute form of DOX-induced cardiomyopathy develops within minutes of intravenous administration and is marked by vasodilation, 36 hypotension, tachycardia, and cardiac arrhythmias. 36, 37 The more serious, chronic form of cardiotoxicity is typically observed within 1 year from the completion of DOX treatment 38 and often manifests as dilated cardiomyopathy, 36 characterized by hypotension, tachycardia, cardiac dilation, 36 and decreased left-ventricular ejection fraction. 36 It is widely believed that the production of free radicals contributes to DOX cardiotoxicity. DOX has the potential for free radical generation because of the presence of a quinone ring C. 35 A 1-electron reduction of DOX leads to the formation of a DOX-semiquinone free radical in the heart cell mitochondria. 39 Although this radical is relatively stable under anaerobic conditions, under aerobic conditions its unpaired electron may be donated during oxidative phosphorylation, which subsequently leads to the production of reactive oxygen species. 8 The risk of cardiac dysfunction appears to be higher for patients treated with a combination of trastuzumab and DOX than in those treated with DOX alone. 14 Activation of the cardiac receptor ErbB2 occurs by the ligand neuregulin (NRG). NRG/ErbB signaling in the myocardium plays a critical role in the protection of cardiomyocytes, promoting cellular survival 23 and cardiac function. [40] [41] [42] The cardiac ErbB2 receptor appears to have a high affinity for trastuzumab. 43 Thus, the binding of trastuzumab to a cardiac ErbB2 receptor interrupts the cardioprotective NRG/ErbB2 signaling. Although partial interference of NRG/ErbB signaling with ErbB2 inhibitors alone does not cause significant cardiac dysfunction, clinical observations suggest that this modulates the response of the myocardium to DOX. 44 This may be because of the location of ErbB2 receptors in the heart. ErbB2 receptors are located in the transverse tubules of the ventricular myocytes and interact with NRG in the Z-band of the sarcomere. 43 Because DOX appears to accumulate in the myofilament, 45 it creates the potential for detrimental interactions between DOX and trastuzumab at the subcellular level.
The mechanism by which trastuzumab enhances DOXinduced cardiac dysfunction is unknown but appears to be related to signal transduction kinetics located downstream of the antibody-receptor interaction. Inhibition of ErbB2 by trastuzumab enhances myocardial injury induced by oxidative stress. This is based on data that indicate that trastuzumab enhances the formation of reactive oxygen species in ErbB2-overexpressing breast cancer cells. 46 In addition, cardiac dysfunction may also result from apoptosis in the myocardium. Akt kinase activity appears to be augmented in cells overexpressing ErbB2. 47 Because of its cell survival characteristics, activation of the Akt pathway contributes to tumor survival. 48 Therefore, the inactivation of ErbB2 and subsequent downregulation of the Akt pathway appears to be an important anticancer mechanism of trastuzumab. However, this same mechanism proves to be detrimental in the myocardium, leading to apoptosis and, ultimately, heart failure.
Cardioprotective Benefits of Exercise in Cancer Therapy
The benefits of chronic endurance exercise training on the cardiovascular system are well established. Daily physical activity, recommended by the American Heart Association, 49 reduces the risk of heart disease by improving circulation, managing weight, improving blood cholesterol levels, and controlling hypertension. The demonstrated beneficial effects of exercise training on cardiovascular disease and mortality support its clinical use in breast cancer patients. Improvements in cardiorespiratory fitness in breast cancer patients have been reported following exercise programs conducted during [50] [51] [52] [53] and after 54, 55 cancer treatment. In addition, a recent meta-analysis reported a significant improvement in exercise capacity as well as a potential link between increased physical activity and decreased all-cause mortality in women with breast cancer. 56 On the other hand, physical inactivity is a risk factor for several chronic diseases, including breast cancer. Recent evidence suggests that physical inactivity confers a population-attributable risk of breast cancer among White women of 2% to 15%. 57 Likewise, Jones et al 58 reported that 36% of breast cancer patients are sedentary.
The findings of several animal model studies [6] [7] [8] [9] [10] [11] [12] [13] support the cardioprotective effect of exercise during DOX therapy. Researchers once believed that physical activity would enhance the deleterious effects of DOX on the myocardium. It was suggested that the increase in myocardial energy demand brought about by exercise would lead to enhanced free radical formation and induce more severe mitochondrial changes. However, an investigation conducted by Combs et al 6 was the first to provide evidence to the contrary. Results from this study revealed that an acute bout of exercise increased survival rates in DOX-treated animals compared with their sedentary counterparts. Since this finding, numerous follow-up investigations on animals have found that both acute 7 and chronic [8] [9] [10] [11] [12] [13] exercise are protective against DOX-induced cardiomyopathy. This cardioprotection is attributed to observed increases in the quantity and activity of the cardiac antioxidants superoxide dismutase, catalase, and glutathione peroxidase 59-61 following acute and chronic exercise. During sustained exercise, the rate of oxygen consumption may increase 20-fold, and this may cause oxidative stress and tissue damage. Therefore, the increase in antioxidant capacity brought about by endurance training is an important adaptation in protecting cardiac cells against injury caused by oxidative stress.
To our knowledge, there have been no published clinical trials examining the role of exercise in preserving cardiac function following trastuzumab and DOX combination treatment. Experimental data on skeletal muscle suggest that exercise increases NRG/ErbB signaling. 62 Therefore, it is plausible to hypothesize that exercise would have a similar effect in the myocardium. Given that cancer patients appear to tolerate a regular physical activity program, exercise therapy is one lifestyle modification that should be recommended to this population to mitigate and/or prevent therapy-induced cardiac dysfunction.
Conclusion
Trastuzumab and DOX treatment are associated with positive clinical outcomes in women diagnosed with breast cancer. 5 However, the concurrent and sequential use of these agents increase a woman's risk for the development of cardiac dysfunction. Although the cardioprotective benefits of exercise are well known in women undergoing breast cancer treatment, [50] [51] [52] [53] [54] [55] [56] its efficacy in patients receiving trastuzumab and DOX therapy have not been examined. Clinical trials that investigate these outcomes in humans are warranted. Should the findings of clinical trials support exercise as a cardioprotective intervention among breast cancer survivors, the implications for rehabilitation specialists in all disciplines are significant. Exercise, as part of the breast cancer treatment trajectory, will hopefully permit a less restrictive use of trastuzumab and DOX and therefore have a positive impact on both length and quality of life.
